CGTX – cognition therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies [Yahoo! Finance]
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
Will Cognition Therapeutics (NASDAQ:CGTX) Spend Its Cash Wisely? [Yahoo! Finance]
Cognition Therapeutics (NASDAQ:CGTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Form EFFECT COGNITION THERAPEUTICS
Form 4 COGNITION THERAPEUTICS For: Dec 18 Filed by: Ricciardi Lisa
Form 4 COGNITION THERAPEUTICS For: Dec 18 Filed by: Caggiano Anthony
Form 4 COGNITION THERAPEUTICS For: Dec 18 Filed by: Doyle John Brendan
Form 8-K COGNITION THERAPEUTICS For: Dec 16
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.